![](/img/cover-not-exists.png)
470: Everolimus Reduces the Risk of Humoral Rejection in De-Novo HTx Recipients Compared to MMF Treated Patients
H.B. Lehmkuhl, N.E. Hiemann, M. Dandel, D. Mai, C. Knosalla, O. Grauhan, R. Meyer, M. Pasic, M. Huebler, Y. Weng, R. HetzerVolume:
27
Year:
2008
Language:
english
DOI:
10.1016/j.healun.2007.11.483
File:
PDF, 63 KB
english, 2008